| Jan'20 | Jan'19 | Jan'18 | Jan'17 | Jan'16 | Jan'15 | Jan'14 | Jan'13 | Jan'12 | Jan'11 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-2,863 | -5,865 | -3,099 | -5,161 | -4,290 | -12,011 | -11,717 | -5,378 | 12 | -2,950 |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||||
Depreciation | |||||||||
137 | 450 | 774 | 1,099 | 1,245 | 1,005 | 718 | 726 | 727 | 850 |
Amortization of capitalized software development costs | |||||||||
1,458 | 1,160 | 2,113 | 2,771 | 3,073 | 3,678 | - | - | - | - |
Amortization of capitalized software development costs | |||||||||
- | - | - | - | - | - | -3,192 | -2,659 | -1,972 | 2,420 |
Amortization of intangible assets | |||||||||
554 | 937 | 1,161 | 1,344 | 1,344 | 1,396 | 1,341 | 583 | 2 | - |
Amortization of other deferred costs | |||||||||
480 | 415 | 341 | 324 | 206 | 189 | 385 | 241 | 11 | 754 |
Amortization of debt discount | |||||||||
- | - | - | - | - | 47 | 4 | 111 | 0 | - |
Valuation adjustment | |||||||||
- | - | -95 | 158 | 1,629 | 2,283 | 140 | 489 | 0 | - |
Valuation adjustments | |||||||||
64 | 126 | - | - | - | - | - | - | - | - |
Loss on early extinguishment of debt | |||||||||
-150 | - | - | - | - | - | - | - | - | - |
Impairment of long-lived assets | |||||||||
- | 3,681 | - | - | - | - | - | - | - | - |
Loss on exit of operating lease | |||||||||
- | -1,034 | - | - | - | - | - | - | - | - |
Loss on disposal of fixed assets | |||||||||
- | -7 | - | - | - | - | - | - | - | - |
Gain on sale of business | |||||||||
- | - | - | 238 | 0 | - | - | - | - | - |
Net loss from conversion of convertible notes | |||||||||
- | - | - | - | - | - | 0 | -5,970 | 0 | - |
Loss on impairment of intangible assets | |||||||||
- | - | - | - | - | 1,952 | 0 | 0 | - | - |
Loss from early extinguishment of debt | |||||||||
- | - | - | - | - | -315 | -160 | 0 | -26 | -1 |
Loss (gain) on disposal of fixed assets | |||||||||
- | - | 16 | -0 | -92 | -180 | 0 | 0 | - | - |
Loss on exit of operating lease | |||||||||
- | - | - | - | - | 234 | 0 | 0 | - | - |
Share-based compensation expense | |||||||||
934 | 629 | 1,109 | 1,787 | 2,386 | 1,934 | 1,660 | 956 | 894 | 678 |
Deferred tax benefit | |||||||||
- | - | - | - | -9 | -720 | 20 | -2,935 | 0 | 997 |
Valuation adjustment for contingent earn-out | |||||||||
- | - | - | - | - | - | 3,580 | 86 | 0 | - |
Other valuation adjustments | |||||||||
- | - | - | 94 | -39 | 128 | -95 | 0 | - | - |
Gain on early extinguishment of lease liability | |||||||||
- | - | - | - | 33 | 0 | - | - | - | - |
Accounts receivable provision (reversal) | |||||||||
-201 | 13 | 234 | 121 | 124 | 441 | 330 | 67 | 159 | - |
Changes in assets and liabilities: | |||||||||
Accounts and contract receivables | |||||||||
-818 | 640 | - | - | - | - | - | - | - | - |
Accounts and contract receivables | |||||||||
- | - | -1,498 | 344 | -2,718 | -2,157 | - | - | - | - |
Accounts and contract receivables | |||||||||
- | - | - | - | - | - | -827 | 2,923 | 1,485 | - |
Accounts and contract receivables | |||||||||
- | - | - | - | - | - | - | - | - | 291 |
Other assets | |||||||||
392 | -466 | 696 | -449 | -575 | 637 | 439 | 1,129 | 47 | -440 |
Accounts payable | |||||||||
-10 | 859 | -695 | -51 | -1,117 | 600 | 275 | 526 | 202 | -322 |
Accrued expenses | |||||||||
-412 | 129 | -117 | -690 | -174 | -1,422 | 259 | 992 | -311 | 608 |
Deferred revenues | |||||||||
-725 | -2,004 | -671 | -341 | 1,405 | -197 | -152 | -180 | 730 | 208 |
Net cash (used in) provided by operating activities | |||||||||
-8 | 1,397 | 2,031 | 1,008 | 5,880 | -3,011 | 212 | -115 | 2,896 | 3,393 |
Cash flows from investing activities: | |||||||||
Purchases of property and equipment | |||||||||
52 | 21 | 49 | 506 | 518 | 2,125 | 152 | 576 | 408 | 530 |
Proceeds from sales of property and equipment | |||||||||
- | 21 | 20 | 0 | - | - | - | - | - | - |
Capitalization of software development costs | |||||||||
3,358 | 3,003 | 1,836 | 1,978 | 0 | 619 | 614 | 1,999 | 2,600 | 2,701 |
Payment for acquisition, net of cash received | |||||||||
- | - | - | - | - | - | - | - | 2,124 | - |
Payment for acquisition | |||||||||
- | - | - | 1,400 | 0 | 6,058 | 3,000 | 12,161 | - | - |
Proceeds from sale of business | |||||||||
- | - | - | 2,000 | 0 | - | - | - | - | - |
Other | |||||||||
- | - | - | - | - | - | - | - | - | -2 |
Net cash used in investing activities | |||||||||
-3,410 | -3,003 | -1,865 | -1,884 | -518 | -8,803 | -3,766 | -14,738 | -5,132 | -3,228 |
Cash flows from financing activities: | |||||||||
Settlement of earn-out consideration | |||||||||
- | - | - | - | - | - | 1,300 | 0 | - | - |
Proceeds from issuance of common stock | |||||||||
9,663 | - | - | - | - | - | 20,586 | 0 | 403 | - |
Offering expense | |||||||||
711 | - | - | - | - | - | - | - | - | - |
Proceeds from term loan | |||||||||
4,000 | - | - | - | - | - | - | - | - | - |
Principal payments on term loan | |||||||||
4,030 | 597 | - | - | - | - | - | - | - | - |
Payments related to settlement of employee shared-based awards | |||||||||
99 | 62 | - | - | - | - | - | - | - | - |
Payment of debt success fee | |||||||||
- | - | - | - | - | - | 1,124 | 467 | 0 | - |
Net change under revolving credit facility | |||||||||
- | - | - | - | - | - | - | - | 1,200 | -300 |
Proceeds from exercise of stock options and stock purchase plan | |||||||||
8 | 44 | 45 | 26 | - | - | - | - | -92 | -141 |
Redemption of Series A Convertible Preferred Stock | |||||||||
5,791 | - | - | - | - | - | - | - | - | - |
Fees paid for redemption of Series A Convertible Preferred Stock | |||||||||
22 | - | - | - | - | - | - | - | - | - |
Proceeds from term loan | |||||||||
- | - | - | - | - | 10,000 | 4,958 | 9,880 | 4,120 | - |
Principal repayments on term loans | |||||||||
- | - | 1,112 | 2,796 | 1,465 | 8,297 | 10,348 | 312 | 0 | - |
Principal payments on capital lease obligations | |||||||||
- | - | 91 | 569 | 815 | 368 | 34 | 0 | 183 | 227 |
Payments related to settlement of employee shared-based awards | |||||||||
- | - | 42 | 11 | 0 | 900 | 0 | 0 | - | - |
Proceeds from private placement | |||||||||
- | - | - | - | - | - | 0 | 12,000 | 0 | - |
Proceeds from exercise of stock options and stock purchase plan | |||||||||
8 | 44 | 45 | 26 | 276 | 552 | 1,356 | 282 | -92 | -141 |
Payment of deferred financing costs | |||||||||
325 | 23 | - | - | -2 | 573 | 115 | 1,271 | 157 | - |
Other | |||||||||
-2 | - | - | - | - | - | - | - | - | - |
Net cash provided by (used in) financing activities | |||||||||
2,691 | -638 | -1,200 | -3,351 | -2,002 | 412 | 13,978 | 20,110 | 3,075 | 213 |
Net decrease in cash and cash equivalents | |||||||||
-727 | -2,244 | - | - | - | - | - | - | - | - |
Net decrease in cash and cash equivalents | |||||||||
- | - | -1,034 | -4,228 | 3,359 | -11,402 | 10,424 | 5,257 | 839 | 378 |
Supplemental cash flow disclosures: | |||||||||
Interest paid, net of amounts capitalized | |||||||||
337 | 417 | 418 | - | - | - | - | - | - | - |
Interest paid | |||||||||
- | - | - | 441 | 917 | 518 | 2,422 | 1,626 | 92 | 74 |
Income taxes paid | |||||||||
9 | 11 | 8 | 5 | -35 | 80 | - | - | - | - |
Supplemental disclosure of non-cash financing activities: | |||||||||
Income taxes (received) paid | |||||||||
- | - | - | - | - | - | 375 | 84 | 20 | 47 |
Convertible note payable issued in conjunction with acquisition | |||||||||
- | - | - | - | - | - | - | - | 3,000 | - |
Conversion of $3,000,000 note payable to common shares | |||||||||
- | - | - | - | - | - | 0 | 3,116 | 0 | - |
Conversion of shares of Series A Preferred Stock to common shares | |||||||||
- | 164 | - | - | - | - | 3,150 | 0 | - | - |
Modification of royalty liability associated with the acquisition of Clinical Analytics | |||||||||
- | 1,644 | - | - | - | - | - | - | - | - |
Issuance of 393,086 shares of common stock, as part of Meta purchase price | |||||||||
- | - | - | - | - | - | 0 | 1,501 | - | - |
Issuance of 400,000 shares of common stock, as part of settlement of earn-out consideration | |||||||||
- | - | - | - | - | - | 2,700 | 0 | - | - |
Issuance of $900,000 note payable as part of settlement of earn-out consideration | |||||||||
- | - | - | - | - | - | 900 | 0 | - | - |
Deemed dividends on Series A Preferred Stock | |||||||||
- | - | - | 875 | 1,336 | 1,038 | 1,180 | 176 | - | - |
Issuance of 393,086 shares of common stock, as part of Meta purchase price | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Deemed dividends on Series A Preferred Stock | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Issuance of warrants to placement agents | |||||||||
- | - | - | - | - | - | 0 | 753 | 0 | - |
Reclassification of warrants from equity to warrants liability | |||||||||
- | - | - | - | - | - | 0 | -4,138 | 0 | - |
Conversion of notes issued in conjunction with the private placement to Series A Preferred Stock, at fair value | |||||||||
- | - | - | - | - | - | 0 | 9,182 | - | - |
Interest rate swap contract | |||||||||
- | - | - | - | - | - | 111 | 0 | - | - |
Conversion of notes issued in conjunction with the private placement to Series A Preferred Stock, at fair value | |||||||||
- | - | - | - | - | - | - | - | 0 | - |